Atherosclerotic Plaque Imaging Project (CPIP)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorLund University

About this trial

The rupture or erosion of an atherosclerotic plaque with thrombosis or embolization often underlie heart attacks and strokes. The early identification of patients with atherosclerotic plaques prone to rupture or erosions, vulnerable plaques (VP), and their treatment before the occurrence of events is, therefore, one of the greatest cardiovascular challenges today. Possible approaches for early detection of VP include imaging techniques allowing visualization of plaque structure, circulating biomarkers and better understanding of the pathophysiologic mechanisms of the disease. In the carotid plaque imaging project the investigators study human atherosclerotic plaques (that are removed by endarterectomy) to disclose their underlying structure and mechanisms, finding possible novel therapeutic targets or markers for VP. The investigators also study plaque structure with imaging methods and try to develop new ways to detect VP using circulating or imaging markers.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients older than 18 years old, male or female that are eligible for carotid endarterectomy due to atherosclerosis and that can provide informed consent.

Disqualifiers

Patients younger than 18 years old that cannot provide informed consent; pregnant.

Trial population

All patients with carotid stenosis undergoing endarterectomy at Skåne University Hospital (SUS), Malmö, Sweden.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Observational study

    Other intervention

Treatment groups

3,500 Participants
are divided into 1 treatment group
Group A: Atherosclerotic Plaque Imaging Project (APIP)1 intervention

Trial outcomes

Primary outcomes

1

Number of participants suffering post-operative cardiovascular events (by 2025)

Post-operative myocardial infarction, stroke, transient ischaemic attack, amaurosis fugax, cardiovascular death (according to Swedish National Registers)

Time frame
Follow up assessment year 2025 (recording of events occurring since 2023)
2

Number of participants suffering post-operative cardiovascular events (by 2027)

Post-operative myocardial infarction, stroke, transient ischaemic attack, amaurosis fugax, cardiovascular death (according to Swedish National Registers)

Time frame
Follow up assessment year 2027 (recording of events occurring since 2025)
3

Number of participants suffering post-operative cardiovascular events (by 2029)

Post-operative myocardial infarction, stroke, transient ischaemic attack, amaurosis fugax, cardiovascular death (according to Swedish National Registers)

Time frame
Follow up assessment year 2029 (recording of events occurring since 2027)

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Lund University

Lead sponsor

Region Skane

Collaborator

The Swedish Research Council

Collaborator

Swedish Heart Lung Foundation

Collaborator

Skåne University Hospital funds (incl. the Medical Training and Research Agreement/ALF)

Collaborator

Swedish Foundation for Strategic Research

Collaborator